A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $58 to $74
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
Buy Rating Reaffirmed for Springworks Therapeutics Amid Promising Outlook for Ogsiveo and Mirdametinib
SpringWorks Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Springworks Therapeutics: Strong Cash Position and Promising Drug Approval Outlook Justify Buy Rating
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $68
Goldman Sachs Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating
SpringWorks Therapeutics Analyst Ratings
H.C. Wainwright Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $76
Wedbush Raises Price Target on SpringWorks Therapeutics to $77 From $75, Maintains Outperform Rating
Buy Rating Affirmed for Springworks Therapeutics on Strong Outlook for Mirdametinib
Springworks Therapeutics (SWTX) Receives a Buy From Barclays
Strong Q2 Performance and Promising Drug Pipeline Bolster Buy Rating for Springworks Therapeutics
Buy Rating Affirmed for Springworks Therapeutics Amid Strong Ogsiveo Sales and Market Expansion Potential
Analysts Are Bullish on These Healthcare Stocks: Novo Nordisk (NVO), Springworks Therapeutics (SWTX)
Barclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)